FX11 | CAS#213971-34-7 | LDHA inhibitor

MedKoo Cat#: 527857 | Name: FX11

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FX11 is a small-molecule inhibitor targeting lactate dehydrogenase A (LDHA), an enzyme pivotal in the glycolytic pathway, particularly in cancer cells exhibiting the Warburg effect. By inhibiting LDHA, FX11 disrupts the conversion of pyruvate to lactate, leading to reduced NAD⁺ regeneration, impaired glycolysis, and subsequent energy depletion in tumor cells. This mechanism induces oxidative stress and apoptosis selectively in cancer cells, making FX11 a valuable tool in cancer metabolism research and a potential therapeutic candidate.

Chemical Structure

FX11

CAS#213971-34-7

Theoretical Analysis

MedKoo Cat#: 527857

Name: FX11

CAS#: 213971-34-7

Chemical Formula: C22H22O4

Exact Mass: 350.1518

Molecular Weight: 350.41

Elemental Analysis: C, 75.41; H, 6.33; O, 18.26

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 550.00	2 Weeks
25mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

FX 11; FX-11; FX11; LDHA Inhibitor FX11

IUPAC/Chemical Name

7-Benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid

InChi Key

LVPYVYFMCKYFCZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H22O4/c1-3-7-16-17-10-13(2)15(11-14-8-5-4-6-9-14)12-18(17)19(22(25)26)21(24)20(16)23/h4-6,8-10,12,23-24H,3,7,11H2,1-2H3,(H,25,26)

SMILES Code

O=C(C1=C2C=C(CC3=CC=CC=C3)C(C)=CC2=C(CCC)C(O)=C1O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

FX-11 (LDHA Inhibitor FX11) is a potent lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 23.3 μM for HeLa cell and a Ki value of 8 μM.

In vitro activity:

FX11 addition increased the oxygen consumption rate (OCR), but decreased the respiratory capacity and ATP synthesis (Fig. 1A,B; Supplementary Materials and Methods). Essentially, FX11, at 14.3 µM concentration, uncoupled the mitochondrial respiratory chain from the phosphorylation system. Reference: Dis Model Mech. 2020 Mar 1; 13(3): dmm041954. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132771/

In vivo activity:

Four of the five tested neuroblastoma cell lines (BE(2)-C, LAN-1, SK-N-SH, and SK-N-AS) demonstrated a significant decrease in the S-phase population, ranging from 2–7% decrease in S phase population (Fig. 3). Taken together, these findings suggest that low micromolar concentration (10 μM) of FX11 blocks progression through the cell cycle with resultant decrease in overall cellular proliferation. Reference: Surgery. 2017 Mar; 161(3): 747–752. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369647/

	Solvent	mg/mL	mM
Solubility
	DMSO	250.0	713.44

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 350.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Krishnamoorthy G, Kaiser P, Abu Abed U, Weiner J 3rd, Moura-Alves P, Brinkmann V, Kaufmann SHE. FX11 limits Mycobacterium tuberculosis growth and potentiates bactericidal activity of isoniazid through host-directed activity. Dis Model Mech. 2020 Mar 30;13(3):dmm041954. doi: 10.1242/dmm.041954. PMID: 32034005; PMCID: PMC7132771. 2. Rellinger EJ, Craig BT, Alvarez AL, Dusek HL, Kim KW, Qiao J, Chung DH. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells. Surgery. 2017 Mar;161(3):747-752. doi: 10.1016/j.surg.2016.09.009. Epub 2016 Dec 2. PMID: 27919448; PMCID: PMC5369647.

In vitro protocol:

In vivo protocol:

1: Rao K, Zhang X, Luo Y, Xia Q, Jin Y, He J. Lactylation orchestrates ubiquitin-independent degradation of cGAS and promotes tumor growth. Cell Rep. 2025 Apr 22;44(4):115441. doi: 10.1016/j.celrep.2025.115441. Epub 2025 Mar 18. PMID: 40106438. 2: Bayindir-Bilgic M, Duman E, Turgut D, Kadikoylu AN, Ekimci-Gurcan N, Ozbey U, Kuskucu A, Bayrak OF. Investigation of the synergistic effect of metformin and FX11 on PANC-1 cell lines. Biol Res. 2025 Mar 17;58(1):15. doi: 10.1186/s40659-025-00592-8. PMID: 40091035; PMCID: PMC11912783. 3: Wang Z, Wu M, Jiang Y, Zhou J, Chen S, Wang Q, Sun H, Deng Y, Zhou Z, Sun M. Biomimetic calcium-chelation nanoparticles reprogram tumor metabolism to enhance antitumor immunity. J Control Release. 2025 Apr 10;380:362-374. doi: 10.1016/j.jconrel.2025.01.046. Epub 2025 Feb 8. PMID: 39832746. 4: Cheng HJ, Chen NF, Chen WF, Wu ZS, Sun YY, Teng WN, Su FW, Sung CS, Wen ZH. Intrathecal lactate dehydrogenase A inhibitors FX11 and oxamate alleviate chronic constriction injury-induced nociceptive sensitization through neuroinflammation and angiogenesis. J Headache Pain. 2024 Nov 25;25(1):207. doi: 10.1186/s10194-024-01916-x. PMID: 39587478; PMCID: PMC11590346. 5: Wen M, Yi N, Mijiti B, Zhao S, Shen G. N6-methyladenosine (m6A) reader HNRNPA2B1 accelerates the cervical cancer cells aerobic glycolysis. J Bioenerg Biomembr. 2024 Dec;56(6):657-668. doi: 10.1007/s10863-024-10042-x. Epub 2024 Oct 19. PMID: 39425888. 6: Chen Y, Luo X, Deng C, Zhao L, Gao H, Zhou J, Peng L, Yang H, Li M, Zhang W, Zhao Y, Fei Y. Immunometabolic alteration of CD4+ T cells in the pathogenesis of primary Sjögren's syndrome. Clin Exp Med. 2024 Jul 22;24(1):163. doi: 10.1007/s10238-024-01429-6. PMID: 39039306; PMCID: PMC11263433. 7: Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, Homsy K, Imada EL, Syamala S, Photopoulos C, Di Matteo A, de Polo A, Storaci AM, Huang Y, Giunchi F, Sheridan PA, Michelotti G, Nguyen QD, Zhao X, Liu Y, Davicioni E, Spratt DE, Sabbioneda S, Maga G, Mucci LA, Ghigna C, Marchionni L, Butler LM, Ellis L, Bordeleau F, Loda M, Vaira V, Labbé DP, Zadra G. Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer. Cancer Res. 2024 Jun 4;84(11):1834-1855. doi: 10.1158/0008-5472.CAN-23-0519. PMID: 38831751; PMCID: PMC11148549. 8: Raish M, Ahmad A, Khan S, Kalam MA. Molecular insights into anti-Protozoal action of natural compounds against Cryptosporidium parvum: a molecular simulation study. J Biomol Struct Dyn. 2025 Mar;43(4):2042-2058. doi: 10.1080/07391102.2023.2293277. Epub 2023 Dec 13. PMID: 38088773. 9: Mi Y, Tang M, Wu Q, Wang Y, Liu Q, Zhu P, Xue X, Liu Y, Chai X, Hou Y, Yan D. NMAAP1 regulated macrophage polarizion into M1 type through glycolysis stimulated with BCG. Int Immunopharmacol. 2024 Jan 5;126:111257. doi: 10.1016/j.intimp.2023.111257. Epub 2023 Nov 21. PMID: 37988910. 10: Nishioku T, Anzai R, Hiramatsu S, Terazono A, Nakao M, Moriyama M. Lactate dehydrogenase A inhibition prevents RANKL-induced osteoclastogenesis by reducing enhanced glycolysis. J Pharmacol Sci. 2023 Dec;153(4):197-207. doi: 10.1016/j.jphs.2023.09.005. Epub 2023 Sep 27. PMID: 37973217. 11: Kitamura F, Semba T, Yasuda-Yoshihara N, Yamada K, Nishimura A, Yamasaki J, Nagano O, Yasuda T, Yonemura A, Tong Y, Wang H, Akiyama T, Matsumura K, Uemura N, Itoyama R, Bu L, Fu L, Hu X, Wei F, Mima K, Imai K, Hayashi H, Yamashita YI, Miyamoto Y, Baba H, Ishimoto T. Cancer-associated fibroblasts reuse cancer- derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. JCI Insight. 2023 Oct 23;8(20):e163022. doi: 10.1172/jci.insight.163022. PMID: 37733442; PMCID: PMC10619496. 12: Chang M, Ellmaker K, Esposito A, Lauricella A, Pa S, Roberts M, Kurt RA. The Impact of Tumor-Associated Macrophages Found at Mammary Carcinoma Sites is Dependent Upon the Tumor Type. Immunol Invest. 2023 Nov;52(7):909-924. doi: 10.1080/08820139.2023.2252463. Epub 2023 Aug 30. PMID: 37647339. 13: Alobaidi B, Hashimi SM, Alqosaibi AI, AlQurashi N, Alhazmi S. Targeting the monocarboxylate transporter MCT2 and lactate dehydrogenase A LDHA in cancer cells with FX-11 and AR-C155858 inhibitors. Eur Rev Med Pharmacol Sci. 2023 Jul;27(14):6605-6617. doi: 10.26355/eurrev_202307_33131. PMID: 37522672. 14: Nguyen Cao TG, Truong Hoang Q, Kang JH, Kang SJ, Ravichandran V, Rhee WJ, Lee M, Ko YT, Shim MS. Bioreducible exosomes encapsulating glycolysis inhibitors potentiate mitochondria-targeted sonodynamic cancer therapy via cancer-targeted drug release and cellular energy depletion. Biomaterials. 2023 Oct;301:122242. doi: 10.1016/j.biomaterials.2023.122242. Epub 2023 Jul 11. PMID: 37473534. 15: Manosalva C, Alarcon P, Quiroga J, Teuber S, Carretta MD, Bustamante H, Lopez-Muñoz R, Hidalgo MA, Burgos RA. Bovine tumor necrosis factor-alpha Increases IL-6, IL-8, and PGE2 in bovine fibroblast-like synoviocytes by metabolic reprogramming. Sci Rep. 2023 Feb 24;13(1):3257. doi: 10.1038/s41598-023-29851-y. PMID: 36828912; PMCID: PMC9958177. 16: Truong Hoang Q, Huynh KA, Nguyen Cao TG, Kang JH, Dang XN, Ravichandran V, Kang HC, Lee M, Kim JE, Ko YT, Lee TI, Shim MS. Piezocatalytic 2D WS2 Nanosheets for Ultrasound-Triggered and Mitochondria-Targeted Piezodynamic Cancer Therapy Synergized with Energy Metabolism-Targeted Chemotherapy. Adv Mater. 2023 May;35(18):e2300437. doi: 10.1002/adma.202300437. Epub 2023 Mar 24. PMID: 36780270. 17: Li K, Romero M, Cañardo M, Garcia D, Diaz A, Blomberg BB, Frasca D. B cells from old mice induce the generation of inflammatory T cells through metabolic pathways. Mech Ageing Dev. 2023 Jan;209:111742. doi: 10.1016/j.mad.2022.111742. Epub 2022 Oct 26. PMID: 36309082. 18: Wu J, Gu X, Zhang J, Mi Z, He Z, Dong Y, Ge W, Ghimire K, Rong P, Wang W, Ma X. 4-OI Protects MIN6 Cells from Oxidative Stress Injury by Reducing LDHA-Mediated ROS Generation. Biomolecules. 2022 Sep 4;12(9):1236. doi: 10.3390/biom12091236. PMID: 36139075; PMCID: PMC9496514. 19: Wu H, Wang Y, Ying M, Jin C, Li J, Hu X. Lactate dehydrogenases amplify reactive oxygen species in cancer cells in response to oxidative stimuli. Signal Transduct Target Ther. 2021 Jun 28;6(1):242. doi: 10.1038/s41392-021-00595-3. PMID: 34176927; PMCID: PMC8236487. 20: Podsednik A, Jiang J, Jacob A, Li LZ, Xu HN. Optical Redox Imaging of Treatment Responses to Nampt Inhibition and Combination Therapy in Triple- Negative Breast Cancer Cells. Int J Mol Sci. 2021 May 25;22(11):5563. doi: 10.3390/ijms22115563. PMID: 34070254; PMCID: PMC8197351.